{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:05:35Z","timestamp":1786629935979,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T00:00:00Z","timestamp":1450310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1038\/jhh.2015.119","type":"journal-article","created":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T10:21:04Z","timestamp":1450347664000},"page":"534-542","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"30","author":[{"given":"S","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Katada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Daida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,17]]},"reference":[{"key":"BFjhh2015119_CR1","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1751-7176.2011.00434.x","volume":"13","author":"AN Long","year":"2011","unstructured":"Long AN, Dagogo-Jack S . Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. J Clin Hypertens (Greenwich) 2011; 13: 244\u2013251.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"BFjhh2015119_CR2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1291\/hypres.19.SupplementI_S1","volume":"19","author":"O Iimura","year":"1996","unstructured":"Iimura O . Insulin resistance and hypertension in Japanese. Hypertens Res 1996; 19: S1\u2013S8.","journal-title":"Hypertens Res"},{"key":"BFjhh2015119_CR3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2337\/diacare.12.8.573","volume":"12","author":"American Diabetes Association","year":"1989","unstructured":"American Diabetes Association. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 1989; 12: 573\u2013579.","journal-title":"Diabetes Care"},{"key":"BFjhh2015119_CR4","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1097\/HJH.0b013e3283469976","volume":"29","author":"G Reboldi","year":"2011","unstructured":"Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P . Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens 2011; 29: 1253\u20131269.","journal-title":"J Hypertens"},{"key":"BFjhh2015119_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861\u2013869.","journal-title":"N Engl J Med"},{"key":"BFjhh2015119_CR6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507\u2013520.","journal-title":"JAMA"},{"key":"BFjhh2015119_CR7","doi-asserted-by":"crossref","unstructured":"Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014 37: 253\u2013390.","DOI":"10.1038\/hr.2014.20"},{"key":"BFjhh2015119_CR8","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1161\/CIRCULATIONAHA.112.096156","volume":"126","author":"Q Gu","year":"2012","unstructured":"Gu Q, Burt VL, Dillon CF, Yoon S . Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010. Circulation 2012; 126: 2105\u20132114.","journal-title":"Circulation"},{"key":"BFjhh2015119_CR9","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","volume":"2","author":"K Ando","year":"2014","unstructured":"Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T et al. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2014; 2: 944\u2013953.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"BFjhh2015119_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1530\/EJE-12-0631","volume":"168","author":"V Fourkiotis","year":"2012","unstructured":"Fourkiotis V, Vonend O, Diederich S, Fischer E, Lang K, Endres S et al. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. Eur J Endocrinol 2012; 168: 75\u201381.","journal-title":"Eur J Endocrinol"},{"key":"BFjhh2015119_CR11","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"MK Nishizaka","year":"2003","unstructured":"Nishizaka MK, Zaman MA, Calhoun DA . Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925\u2013930.","journal-title":"Am J Hypertens"},{"key":"BFjhh2015119_CR12","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/ncpneph0575","volume":"3","author":"AS Bomback","year":"2007","unstructured":"Bomback AS, Klemmer PJ . The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3: 486\u2013492.","journal-title":"Nat Clin Pract Nephrol"},{"key":"BFjhh2015119_CR13","unstructured":"Higgins JPT, Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated march 2011). Available at \n                    http:\/\/community.cochrane.org\/handbook\/\n                    \n                  ."},{"key":"BFjhh2015119_CR14","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1097\/HJH.0b013e3283638b1a","volume":"31","author":"CS Oxlund","year":"2013","unstructured":"Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA . Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 2013; 31: 2094\u20133102.","journal-title":"J Hypertens"},{"key":"BFjhh2015119_CR15","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","volume":"24","author":"AH van den Meiracker","year":"2006","unstructured":"van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D et al. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens 2006; 24: 2285\u20132292.","journal-title":"J Hypertens"},{"key":"BFjhh2015119_CR16","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s00125-008-0972-5","volume":"51","author":"K Swaminathan","year":"2008","unstructured":"Swaminathan K, Davies J, George J, Rajendra NS, Morris AD, Struthers AD . Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia 2008; 51: 762\u2013768.","journal-title":"Diabetologia"},{"key":"BFjhh2015119_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1177\/1470320312460290","volume":"14","author":"SE Nielsen","year":"2013","unstructured":"Nielsen SE, Schjoedt KJ, Rossing K, Persson F, Schalkwijk CG, Stehouwer CD et al. Levels of NU-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. J Renin Angiotensin Aldosterone Syst 2013; 14: 161\u2013166.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"BFjhh2015119_CR18","doi-asserted-by":"publisher","first-page":"714","DOI":"10.2310\/JIM.0b013e31816d78e9","volume":"56","author":"MG Saklayen","year":"2008","unstructured":"Saklayen MG, Gyebi LK, Tasosa J, Yap J . Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. J Investig Med 2008; 56: 714\u2013719.","journal-title":"J Investig Med"},{"key":"BFjhh2015119_CR19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1440-1681.2006.04390.x","volume":"33","author":"S Ogawa","year":"2006","unstructured":"Ogawa S, Takeuchi K, Mori T, Nako K, Ito S . Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. Clin Exp Pharmacol Physiol 2006; 33: 477\u2013479.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"BFjhh2015119_CR20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/jdi.12029","volume":"4","author":"M Hase","year":"2013","unstructured":"Hase M, Babazono T, Ujihara N, Uchigata Y . Comparison of spironolactone and trichlormethiazide as add-on therapy to renin-angiotensin blockade for reduction of albuminuria in diabetic patients. J Diabetes Investig 2013; 4: 316\u2013319.","journal-title":"J Diabetes Investig"},{"key":"BFjhh2015119_CR21","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1093\/ndt\/gft281","volume":"28","author":"A Esteghamati","year":"2013","unstructured":"Esteghamati A, Noshad S, Jarrah S, Mousavizadeh M, Khoee SH, Nakhjavani M . Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial. Nephrol Dial Transplant 2013; 28: 2823\u20132833.","journal-title":"Nephrol Dial Transplant"},{"key":"BFjhh2015119_CR22","doi-asserted-by":"publisher","first-page":"985","DOI":"10.4158\/EP.14.8.985","volume":"14","author":"MB Davidson","year":"2008","unstructured":"Davidson MB, Wong A, Hamrahian AH, Stevens M, Siraj ES . Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors. Endocr Pract 2008; 14: 985\u2013992.","journal-title":"Endocr Pract"},{"key":"BFjhh2015119_CR23","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1172\/JCI43124","volume":"121","author":"S Shibata","year":"2011","unstructured":"Shibata S, Mu S, Kawarazaki H, Muraoka K, Ishizawa K, Yoshida S et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest 2011; 121: 3233\u20133243.","journal-title":"J Clin Invest"},{"key":"BFjhh2015119_CR24","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.107.748640","volume":"117","author":"C Guo","year":"2008","unstructured":"Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008; 117: 2253\u20132261.","journal-title":"Circulation"},{"key":"BFjhh2015119_CR25","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1292\/jvms.12-0007","volume":"74","author":"T Homma","year":"2012","unstructured":"Homma T, Fujisawa M, Arai K, Ishii M, Sada T, Ikeda M . Spironolactone, but not eplerenone, impairs glucose tolerance in a rat model of metabolic syndrome. J Vet Med Sci 2012; 74: 1015\u20131022.","journal-title":"J Vet Med Sci"},{"key":"BFjhh2015119_CR26","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2337\/dc08-1709","volume":"32","author":"D Preiss","year":"2009","unstructured":"Preiss D, Zetterstrand S, McMurray JJ, Ostergren J, Michelson EL, Granger CB et al. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care 2009; 32: 915\u2013920.","journal-title":"Diabetes Care"},{"key":"BFjhh2015119_CR27","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1161\/HYPERTENSIONAHA.111.00662","volume":"61","author":"A Vaidya","year":"2013","unstructured":"Vaidya A, Underwood PC, Hopkins PN, Jeunemaitre X, Ferri C, Williams GH et al. Abnormal aldosterone physiology and cardiometabolic risk factors. Hypertension 2013; 61: 886\u2013893.","journal-title":"Hypertension"},{"key":"BFjhh2015119_CR28","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1038\/nm.2891","volume":"18","author":"A McCurley","year":"2012","unstructured":"McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med 2012; 18: 1429\u20131433.","journal-title":"Nat Med"},{"key":"BFjhh2015119_CR29","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1097\/HJH.0b013e328338bb37","volume":"28","author":"K Ito","year":"2010","unstructured":"Ito K, Hirooka Y, Sunagawa K . Blockade of mineralocorticoid receptors improves salt-induced left-ventricular systolic dysfunction through attenuation of enhanced sympathetic drive in mice with pressure overload. J Hypertens 2010; 28: 1449\u20131458.","journal-title":"J Hypertens"},{"key":"BFjhh2015119_CR30","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/1470320310390404","volume":"12","author":"Y Yano","year":"2011","unstructured":"Yano Y, Hoshide S, Tamaki N, Nagata M, Sasaki K, Kanemaru Y et al. Efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients: the Jichi-Eplerenone Treatment (JET) study. J Renin Angiotensin Aldosterone Syst 2011; 12: 340\u2013347.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"BFjhh2015119_CR31","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1055\/s-2005-870240","volume":"37","author":"D Kraus","year":"2005","unstructured":"Kraus D, J\u00e4ger J, Meier B, Fasshauer M, Klein J . Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res 2005; 37: 455\u2013459.","journal-title":"Horm Metab Res"},{"key":"BFjhh2015119_CR32","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"M Epstein","year":"2006","unstructured":"Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940\u2013951.","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFjhh2015119_CR33","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev.pathol.4.110807.092150","volume":"6","author":"S Kanwar","year":"2011","unstructured":"Kanwar S, Sun L, Xie P, Liu FY, Chen S . A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol 2011; 6: 395\u2013423.","journal-title":"Annu Rev Pathol"},{"key":"BFjhh2015119_CR34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","volume":"40","author":"H Krum","year":"2002","unstructured":"Krum H, Nolly H, Workman D, He W, Roniker B, Krause S et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002; 40: 117\u2013123.","journal-title":"Hypertension"},{"key":"BFjhh2015119_CR35","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","volume":"29","author":"HK Parthasarathy","year":"2011","unstructured":"Parthasarathy HK, M\u00e9nard J, White WB, Young WF Jr, Williams GH, Williams B et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011; 29: 980\u2013990.","journal-title":"J Hypertens"},{"key":"BFjhh2015119_CR36","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N Chapman","year":"2007","unstructured":"Chapman N, Dobson J, Wilson S, Dahl\u00f6f B, Sever PS, Wedel H et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 839\u2013845.","journal-title":"Hypertension"},{"key":"BFjhh2015119_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","volume":"217","author":"SM Garthwaite","year":"2004","unstructured":"Garthwaite SM, McMahon EG . The evolution of aldosterone antagonists. Mol Cell Endocrinol 2004; 217: 27\u201331.","journal-title":"Mol Cell Endocrinol"},{"key":"BFjhh2015119_CR38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/hr.2013.80","volume":"37","author":"K Shimamoto","year":"2014","unstructured":"Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014; 37: 253\u2013390.","journal-title":"Hypertens Res"},{"key":"BFjhh2015119_CR39","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, B\u00f6hm M et al. 2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159\u20132219.","journal-title":"Eur Heart J"},{"key":"BFjhh2015119_CR40","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507\u2013520.","journal-title":"JAMA"},{"key":"BFjhh2015119_CR41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/jch.12237","volume":"16","author":"MA Weber","year":"2014","unstructured":"Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) 2014; 16: 14\u201326.","journal-title":"J Clin Hypertens (Greenwich)"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/jhh2015119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/jhh2015119","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/jhh2015119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:36:50Z","timestamp":1684431410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/jhh2015119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,17]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["BFjhh2015119"],"URL":"https:\/\/doi.org\/10.1038\/jhh.2015.119","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,17]]},"assertion":[{"value":"21 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ST and JK are employees of Pfizer Japan Inc. HD has received lecture fees from Takeda Pharmaceutical Co., Philips Respironics GK, Nippon Boehringer Ingelheim Co., Astellas Pharma Inc., Sanofi-Aventis, MSD, Bristol-Myers Squibb Company, Astra-Zeneca, Otsuka Pharmaceutical Co., Pfizer Japan Inc., Daiichi-Sankyo Company, Bayer Yakuhin, Ltd, Sanwakagaku Kenkyusho, Eisai Co., Ltd, and research funds from MDS, Astra-Zeneca, Astellas Pharma Inc., Bayer Yakuhin, Ltd, Nippon Boehringer Ingelheim Co., Daiichi-Sankyo Company, Kowa Pharmaceutical Company. FK and KY declare no potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}